Impexpharm (შპს იმპექსფარმი) — Georgia Financials

Georgia Financials

panel 2026-09-21Ask

Impexpharm (შპს იმპექსფარმი) — Georgia Financials

as filed · GEL, thousands

Line item	2017	2018	2019	2020	2021	2022	2023	2024	CAGR
Total Revenue	53,279	60,980	81,037	93,314	108,941	109,410	102,458	110,181	+10.9%
Total COGS	43,005	49,510	64,167	71,960	84,371	82,706	71,846	77,287	+8.7%
Gross Profit	10,274	11,470	16,869	21,354	24,570	26,704	30,612	32,894	+18.1%
Gross Margin	19.3%	18.8%	20.8%	22.9%	22.6%	24.4%	29.9%	29.9%
	3,627	8,821	14,895	14,758	16,822	19,403	26,454	25,933	+32.4%
EBITDA	6,647	2,649	1,975	6,595	7,748	7,302	4,157	6,960	+0.7%
EBITDA Margin	12.5%	4.3%	2.4%	7.1%	7.1%	6.7%	4.1%	6.3%
Total D&A	552	610	734	3,488	4,066	4,351	4,927	5,045	+37.2%
EBIT / Operating Income	6,095	2,039	1,241	3,108	3,683	2,951	769	1,915	-15.2%
Total Interest Income	1,900	1,149	1,348	1,449	1,762	1,976	1,094	438	-18.9%
Total Interest Expense	0	0	0	1,193	1,328	1,280	1,558	1,714	+9.5%
	6	1,657	5,603	4,200	6,030	7,831	2,721	2,744	nmf
Profit Before Tax	7,989	4,845	8,193	7,563	10,147	11,477	1,488	3,384	-11.5%
Total Income Tax	0	0	0	0	8	39	24	20	+37.5%
Net Profit / (Loss)	4,753	4,803	8,147	6,728	9,084	10,163	153	2,894	-6.8%
Net Margin	8.9%	7.9%	10.1%	7.2%	8.3%	9.3%	0.1%	2.6%